Eyebright Medical(688050) Zheng Quan Zhi Xing·2025-05-29 12:19Core Viewpoint - The company, Aibo Medical, has approved the use of raised funds to replace self-raised funds that were previously invested in projects and paid issuance expenses, totaling RMB 40,556,134.86 [1][2] Fundraising Overview - Aibo Medical issued 3,593,615 shares at a price of RMB 79.20 per share, raising a total of RMB 284,614,308.00 in 2024 [1] - The net amount raised after deducting related issuance expenses is less than the intended investment amount, allowing the company to use self-raised funds for initial investments [1] Investment Project Details - The total investment amount for the projects is RMB 422,430,700, with RMB 284,614,308 intended to be funded by the raised funds [1] - The company has pre-invested self-raised funds in the projects, with specific amounts detailed for each project [1] Approval Process - The board of directors and the supervisory board approved the proposal on May 29, 2025, confirming compliance with regulations regarding the replacement of funds within six months of the funds being received [1][2] Opinions from Supervisory Board and Auditors - The supervisory board agrees that the replacement of self-raised funds aligns with the company's interests and complies with relevant laws and regulations [2] - The auditing firm, Xinyong Zhonghe, confirmed that the management's report accurately reflects the situation regarding the use of self-raised funds [2]